Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells.

Benjamin D, Robay D, Hindupur SK, Pohlmann J, Colombi M, El-Shemerly MY, Maira SM, Moroni C, Lane HA, Hall MN.

Cell Rep. 2018 Dec 11;25(11):3047-3058.e4. doi: 10.1016/j.celrep.2018.11.043.

2.

The novel microtubule targeting agent BAL101553 in combination with radiotherapy in treatment-refractory tumor models.

Sharma A, Broggini-Tenzer A, Vuong V, Messikommer A, Nytko KJ, Guckenberger M, Bachmann F, Lane HA, Pruschy M.

Radiother Oncol. 2017 Sep;124(3):433-438. doi: 10.1016/j.radonc.2017.07.024. Epub 2017 Aug 7.

PMID:
28797699
3.

Syrosingopine sensitizes cancer cells to killing by metformin.

Benjamin D, Colombi M, Hindupur SK, Betz C, Lane HA, El-Shemerly MY, Lu M, Quagliata L, Terracciano L, Moes S, Sharpe T, Wodnar-Filipowicz A, Moroni C, Hall MN.

Sci Adv. 2016 Dec 23;2(12):e1601756. doi: 10.1126/sciadv.1601756. eCollection 2016 Dec.

4.

The Novel Tubulin-Binding Checkpoint Activator BAL101553 Inhibits EB1-Dependent Migration and Invasion and Promotes Differentiation of Glioblastoma Stem-like Cells.

Bergès R, Tchoghandjian A, Honoré S, Estève MA, Figarella-Branger D, Bachmann F, Lane HA, Braguer D.

Mol Cancer Ther. 2016 Nov;15(11):2740-2749. Epub 2016 Aug 18.

5.

Shell hardness and compressive strength of the Eastern oyster, Crassostrea virginica, and the Asian oyster, Crassostrea ariakensis.

Lombardi SA, Chon GD, Lee JJ, Lane HA, Paynter KT.

Biol Bull. 2013 Dec;225(3):175-83.

PMID:
24445443
6.

Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.

Martin LA, Pancholi S, Farmer I, Guest S, Ribas R, Weigel MT, Thornhill AM, Ghazoui Z, A'Hern R, Evans DB, Lane HA, Johnston SR, Dowsett M.

Breast Cancer Res. 2012 Oct 17;14(5):R132. doi: 10.1186/bcr3330.

7.

Research and innovation in the development of everolimus for oncology.

Lebwohl D, Thomas G, Lane HA, O'Reilly T, Escudier B, Yao JC, Pavel M, Franz D, Berg W, Baladi JF, Stewart J, Motzer RJ.

Expert Opin Drug Discov. 2011 Mar;6(3):323-38. doi: 10.1517/17460441.2011.558079. Epub 2011 Feb 17.

PMID:
22647206
8.

Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo.

O'Reilly T, McSheehy PM, Wartmann M, Lassota P, Brandt R, Lane HA.

Anticancer Drugs. 2011 Jan;22(1):58-78. doi: 10.1097/CAD.0b013e3283400a20.

PMID:
20890178
9.

Anti-Angiogenic/Vascular Effects of the mTOR Inhibitor Everolimus Are Not Detectable by FDG/FLT-PET.

Honer M, Ebenhan T, Allegrini PR, Ametamey SM, Becquet M, Cannet C, Lane HA, O'Reilly TM, Schubiger PA, Sticker-Jantscheff M, Stumm M, McSheehy PM.

Transl Oncol. 2010 Aug 1;3(4):264-75.

10.

Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model.

O'Reilly T, Lane HA, Wood JM, Schnell C, Littlewood-Evans A, Brueggen J, McSheehy PM.

Cancer Chemother Pharmacol. 2011 Jan;67(1):193-200. doi: 10.1007/s00280-010-1307-z. Epub 2010 May 30.

PMID:
20512579
11.

Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents.

O'Reilly T, McSheehy PM, Kawai R, Kretz O, McMahon L, Brueggen J, Bruelisauer A, Gschwind HP, Allegrini PR, Lane HA.

Cancer Chemother Pharmacol. 2010 Mar;65(4):625-39. doi: 10.1007/s00280-009-1068-8. Epub 2009 Sep 27.

PMID:
19784839
12.

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS.

J Clin Oncol. 2009 Jun 1;27(16):2630-7. doi: 10.1200/JCO.2008.18.8391. Epub 2009 Apr 20.

PMID:
19380449
13.

Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition.

Breuleux M, Klopfenstein M, Stephan C, Doughty CA, Barys L, Maira SM, Kwiatkowski D, Lane HA.

Mol Cancer Ther. 2009 Apr;8(4):742-53. doi: 10.1158/1535-7163.MCT-08-0668.

14.

Optimal targeting of the mTORC1 kinase in human cancer.

Lane HA, Breuleux M.

Curr Opin Cell Biol. 2009 Apr;21(2):219-29. doi: 10.1016/j.ceb.2009.01.016. Epub 2009 Feb 21. Review.

PMID:
19233631
15.

AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001.

Marinov M, Ziogas A, Pardo OE, Tan LT, Dhillon T, Mauri FA, Lane HA, Lemoine NR, Zangemeister-Wittke U, Seckl MJ, Arcaro A.

Clin Cancer Res. 2009 Feb 15;15(4):1277-87. doi: 10.1158/1078-0432.CCR-08-2166.

16.

mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.

Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T.

Clin Cancer Res. 2009 Mar 1;15(5):1612-22. doi: 10.1158/1078-0432.CCR-08-2057. Epub 2009 Feb 17.

17.

Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice.

Fujishita T, Aoki K, Lane HA, Aoki M, Taketo MM.

Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13544-9. doi: 10.1073/pnas.0800041105. Epub 2008 Sep 3.

18.

PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel.

Yang L, Clarke MJ, Carlson BL, Mladek AC, Schroeder MA, Decker P, Wu W, Kitange GJ, Grogan PT, Goble JM, Uhm J, Galanis E, Giannini C, Lane HA, James CD, Sarkaria JN.

Clin Cancer Res. 2008 Jun 15;14(12):3993-4001. doi: 10.1158/1078-0432.CCR-07-4152.

19.

RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR.

Croyle M, Akeno N, Knauf JA, Fabbro D, Chen X, Baumgartner JE, Lane HA, Fagin JA.

Cancer Res. 2008 Jun 1;68(11):4183-91. doi: 10.1158/0008-5472.CAN-08-0413.

20.

Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.

Johansson G, Mahller YY, Collins MH, Kim MO, Nobukuni T, Perentesis J, Cripe TP, Lane HA, Kozma SC, Thomas G, Ratner N.

Mol Cancer Ther. 2008 May;7(5):1237-45. doi: 10.1158/1535-7163.MCT-07-2335.

21.

The Ret receptor tyrosine kinase pathway functionally interacts with the ERalpha pathway in breast cancer.

Boulay A, Breuleux M, Stephan C, Fux C, Brisken C, Fiche M, Wartmann M, Stumm M, Lane HA, Hynes NE.

Cancer Res. 2008 May 15;68(10):3743-51. doi: 10.1158/0008-5472.CAN-07-5100.

22.

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.

O'Donnell A, Faivre S, Burris HA 3rd, Rea D, Papadimitrakopoulou V, Shand N, Lane HA, Hazell K, Zoellner U, Kovarik JM, Brock C, Jones S, Raymond E, Judson I.

J Clin Oncol. 2008 Apr 1;26(10):1588-95. doi: 10.1200/JCO.2007.14.0988. Epub 2008 Mar 10.

PMID:
18332470
23.

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Ramon y Cajal S, Jones S, Vidal L, Shand N, Macarulla T, Ramos FJ, Dimitrijevic S, Zoellner U, Tang P, Stumm M, Lane HA, Lebwohl D, Baselga J.

J Clin Oncol. 2008 Apr 1;26(10):1603-10. doi: 10.1200/JCO.2007.14.5482. Epub 2008 Mar 10. Erratum in: J Clin Oncol. 2010 Dec 20;28(36):5350.

PMID:
18332469
24.

Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data.

Tanaka C, O'Reilly T, Kovarik JM, Shand N, Hazell K, Judson I, Raymond E, Zumstein-Mecker S, Stephan C, Boulay A, Hattenberger M, Thomas G, Lane HA.

J Clin Oncol. 2008 Apr 1;26(10):1596-602. doi: 10.1200/JCO.2007.14.1127. Epub 2008 Mar 10.

PMID:
18332467
25.

The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells.

Akeno-Stuart N, Croyle M, Knauf JA, Malaguarnera R, Vitagliano D, Santoro M, Stephan C, Grosios K, Wartmann M, Cozens R, Caravatti G, Fabbro D, Lane HA, Fagin JA.

Cancer Res. 2007 Jul 15;67(14):6956-64.

26.

The mammalian target of rapamycin kinase and tumor growth inhibition.

Boulay A, Lane HA.

Recent Results Cancer Res. 2007;172:99-124. Review. No abstract available.

PMID:
17607938
27.

Noninvasive assessment of preclinical atherosclerosis.

Lane HA, Smith JC, Davies JS.

Vasc Health Risk Manag. 2006;2(1):19-30. Review.

28.

Impaired vasoreactivity in bodybuilders using androgenic anabolic steroids.

Lane HA, Grace F, Smith JC, Morris K, Cockcroft J, Scanlon MF, Davies JS.

Eur J Clin Invest. 2006 Jul;36(7):483-8.

PMID:
16796605
29.
30.

Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.

Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O'Reilly T, Evans DB, Chen S, Lane HA.

Clin Cancer Res. 2005 Jul 15;11(14):5319-28.

31.

Flap suturing with proparacaine for recurrent epithelial ingrowth following laser in situ keratomileusis surgery.

Spanggord HM, Epstein RJ, Lane HA, Candal EM, Klein SR, Majmudar PA, Dennis RF.

J Cataract Refract Surg. 2005 May;31(5):916-21.

PMID:
15975456
32.

ERBB receptors and cancer: the complexity of targeted inhibitors.

Hynes NE, Lane HA.

Nat Rev Cancer. 2005 May;5(5):341-54. Review. Erratum in: Nat Rev Cancer. 2005 Jul;5(7):580.

PMID:
15864276
33.

The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O'Reilly T, Natt F, Hall J, Lane HA, Thomas G.

Cell. 2005 Mar 25;120(6):747-59.

34.

Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.

Goudar RK, Shi Q, Hjelmeland MD, Keir ST, McLendon RE, Wikstrand CJ, Reese ED, Conrad CA, Traxler P, Lane HA, Reardon DA, Cavenee WK, Wang XF, Bigner DD, Friedman HS, Rich JN.

Mol Cancer Ther. 2005 Jan;4(1):101-12.

35.

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.

Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.

Cancer Res. 2004 Jul 15;64(14):4931-41.

36.

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways.

Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA, Sellers WR.

Nat Med. 2004 Jun;10(6):594-601. Epub 2004 May 23.

PMID:
15156201
37.

Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.

Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, Haller R, Tobler S, Heusser C, O'Reilly T, Stolz B, Marti A, Thomas G, Lane HA.

Cancer Res. 2004 Jan 1;64(1):252-61.

38.

Endothelial function and coagulant factors in growth hormone-treated hypopituitary adults receiving desmopressin.

Smith JC, Lane HA, Lewis J, Dann S, Goodfellow J, Collins P, Evans LM, Scanlon MF, Davies JS.

J Clin Endocrinol Metab. 2003 May;88(5):2152-6.

PMID:
12727969
39.

Prophylactic use of mitomycin-C in the management of a buttonholed LASIK flap.

Lane HA, Swale JA, Majmudar PA.

J Cataract Refract Surg. 2003 Feb;29(2):390-2.

PMID:
12648655
41.

The role of overexpressed HER2 in transformation.

Neve RM, Lane HA, Hynes NE.

Ann Oncol. 2001;12 Suppl 1:S9-13. Review.

PMID:
11521729
42.

Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling.

Lane HA, Motoyama AB, Beuvink I, Hynes NE.

Ann Oncol. 2001;12 Suppl 1:S21-2. Review.

PMID:
11521716
43.

Myc and mammary cancer: Myc is a downstream effector of the ErbB2 receptor tyrosine kinase.

Hynes NE, Lane HA.

J Mammary Gland Biol Neoplasia. 2001 Jan;6(1):141-50. Review.

PMID:
11467449
44.

The ErbB signaling network: receptor heterodimerization in development and cancer.

Olayioye MA, Neve RM, Lane HA, Hynes NE.

EMBO J. 2000 Jul 3;19(13):3159-67. Review. No abstract available.

45.

Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells.

Neve RM, Sutterlüty H, Pullen N, Lane HA, Daly JM, Krek W, Hynes NE.

Oncogene. 2000 Mar 23;19(13):1647-56.

46.
47.

NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways.

Daly JM, Olayioye MA, Wong AM, Neve R, Lane HA, Maurer FG, Hynes NE.

Oncogene. 1999 Jun 10;18(23):3440-51.

48.

On the regulation and function of human polo-like kinase 1 (PLK1): effects of overexpression on cell cycle progression.

Mundt KE, Golsteyn RM, Lane HA, Nigg EA.

Biochem Biophys Res Commun. 1997 Oct 20;239(2):377-85.

PMID:
9344838
49.

Cell-cycle control: POLO-like kinases join the outer circle.

Lane HA, Nigg EA.

Trends Cell Biol. 1997 Feb;7(2):63-8.

PMID:
17708908
50.

Supplemental Content

Support Center